ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 0513 • ACR Convergence 2022

    The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

    Jessica Bloom1, Kaci Pickett2, Lori Silveira2, David Cuthbertson3, Nader Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Paul Monach8, Larry Moreland1, Christian Pagnoux9, Rennie Rhee10, Philip Seo11, Ulrich Specks12, Kenneth J. Warrington12, Robert Fuhlbrigge1 and Peter Merkel10, 1University of Colorado, Denver, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of South Florida, Tampa, FL, 4McMaster University, Hamilton, ON, Canada, 5University of Texas Dell Medical School, Austin, TX, 6Cleveland Clinic, Cleveland, OH, 7University of Pennsylvania, Philadelphia, 8VA Boston Healthcare System, Boston, MA, 9Mount Sinai Hospital, Toronto, ON, Canada, 10University of Pennsylvania, Philadelphia, PA, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, Rochester, MN

    Background/Purpose: Clinical characteristics and outcomes often differ between children and adults diagnosed with the same rheumatic condition; however, such comparative data is limited in ANCA-associated…
  • Abstract Number: 1085 • ACR Convergence 2022

    Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort

    Sharanya Joginpalli1, Alvaro Orjuela2, Marietta De Guzman3 and Emily Frierson2, 1Baylor College of Medicine- Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine/ Texas Children's Hospital, Houston, TX

    Background/Purpose: Therapeutic plasma exchange (TPE) is used in anti-neutrophil cytoplasmic antibody associated vasculitis (AAV) as adjunct treatment for severe disease. There is paucity of data…
  • Abstract Number: 1558 • ACR Convergence 2022

    Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain

    Alba Herrero-Morant1, Carmen Alvarez Reguera2, Lara Sánchez-Bilbao2, David Martínez-López2, guillermo Suárez-Amorin2, Raúl fernández-ramón2, José Luis Martín-Varillas3, Cristina Mata4, Miguel Ángel González-Gay5 and Ricardo Blanco6, 1Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital de Laredo, Laredo, Cantabria, Spain, 4Hospital Laredo, Santander, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 6Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Behçet's disease (BD) may present with different clinical phenotypes. Ocular and Neurobehçet's Disease (NBD) are severe complications. Data on NBD epidemiology, clinical phenotype and…
  • Abstract Number: 1616 • ACR Convergence 2022

    Drug Use and Pregnancy Outcomes in Pregnant Women with Systemic Vasculitis: A Nation Wide Cohort Study

    Camille Mettler1, Nathanaël Beeker2, Mathis Collier2, Veronique Le Guern3, Benjamin Terrier4 and Laurent Chouchana5, 1Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases, Cochin Hospital, Paris, France, 2Unité de Recherche clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, 3Hôpital Cochin, Paris, France, 4National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 5Pharmacology department, Centre Régional de Pharmacovigilance, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose: Women of childbearing age are rarely affected by systemic vasculitis (SV), explaining the lack of solid data regarding pregnancy in these patients. The objective…
  • Abstract Number: 0436 • ACR Convergence 2022

    Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study

    Julien Culerrier1, Yann Nguyen2, Omer Karadag3, Sule Yasar Bilge4, Tuba DEMIRCI YILDIRIM5, Tahir Saygin Öğüt6, Veli Yazisiz6, Cemal Bes7, Ayse Cefle8, Oznur Sadioglu Cagdas9, Ayten Yazici8, Andreas Kronbichler10, David Jayne10, Alexis Regent11, Vitor Teixeira12, Sylvain Marchand-Adam13, PIerre Duffau14, Saskia Oro15, Baptiste Andre16, Luminita Luca17, Sarah Lechtman18, Achille Aouba19, Celine Lebas20, Amélie Servettaz21, Amandine Dernoncourt22, Marc Ruivard23, Anne-Marie Milesi24, Vincent Poindron25, Patrick Jego26, Roberto Padoan27, Paolo Delvino28, Frédéric Vandergheynst29, Christian Pagnoux30, Elaine Yacyshyn31, Peter Lamprecht32, Oliver Flossmann33, Xavier Puéchal11 and Benjamin Terrier11, 1Université Paris Cité, Paris, France, Paris, France, 2AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, 3Hacettepe University, Ankara, Turkey, 4Eskişehir Osmangazi Üniversity, Eskisehir, Turkey, 5Dokuz Eylul University, İzmir, Turkey, 6Akdeniz University, Antalya, Turkey, 7Bahçeşehi University, Istanbul, Turkey, 8Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, 9Kocaeli University, Kocaeli, Turkey, 10University of Cambridge, Cambridge, United Kingdom, 11National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 12Hospital de Faro, CHUA, Lisbon, Portugal, 13Tours University Hospital, Tours, France, 14CHU Bordeaux, Bordeaux, France, 15Assistance Publique - Hôpitaux de Paris., Paris, France, 16Hôpital de la Timone, Marseille, Marseille, France, 17CHU de Poitiers, Poitiers, France, 18CHU Nice, Nice, France, 19Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, 20CHRU Lille, Lille, France, 21CHU Reims, Reims, France, 22CHU Amiens - Picardie, Amiens, France, 23Clermont Ferrand University Hospital, Clermont-Ferrand, France, 24Centre hospitalier de Vichy, Vichy, France, 25Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 26CHU Rennes, Paris, France, 27University of Padova, Padova, Italy, 28Università di Pavia, Vercelli, Italy, 29Professeur de Médecine Interne et Sémiologie médicale, Directeur de la Clinique de Médecine Interne Générale, Université Libre de Bruxelles, Bruxelles, France, 30Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 31University of Alberta, Edmonton, AB, Canada, 32Department of Rheumatology University of Lübeck Ratzeburger Allee, Lübeck, Germany, 33Royal Berkshire Hospital, Reading, United Kingdom

    Background/Purpose: ANCA-associated vasculitides (AAV) induced by anti-thyroid drugs (ATD) is a well-known entity. However, characteristics, requirement for immunosuppressive agents and the risk of relapse remain…
  • Abstract Number: 0469 • ACR Convergence 2022

    Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis

    Loukas Kakoullis and Shiv Sehra, Mount Auburn Hospital, Cambridge, MA

    Background/Purpose: Corticosteroids are the cornerstone of therapy in patients with giant cell arteritis (GCA). Tapering regiments vary considerably in both dose and duration, while relapses…
  • Abstract Number: 0524 • ACR Convergence 2022

    A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis

    Peter Merkel1, Bernhard Hellmich2, Anja Pfaff3, Carina Müller4, Elena Startseva3 and David Jayne5, 1University of Pennsylvania, Philadelphia, PA, 2Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, 3InflaRx, Jena, Germany, 4Metronomia Clinical Research, Munich, Germany, 5University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Induction of remission for severe ANCA-associated vasculitis [granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)] utilizes rituximab (RTX) or cyclophosphamide (CYC) and tapering doses…
  • Abstract Number: 1202 • ACR Convergence 2022

    Clinical Profile and Trend of Vasculitis in Patients with Acute Coronary Syndrome – Insight from National Database 2010 to 2019

    Palak Shah1, Ana Arevalo2, Rasha Alaameri3, Brinda Basida4, Urja Nagadia5, Sanket Basida5, shobhana Chaudhari6 and Monil Majmundar7, 1Metropolitan Hospital Center, New York Medical College, New York, NY, 2University of Chicago, Chicago, IL, 3New York Medical College/ Metropolitan Program, New York, NY, 4DMC/Sinai Grace Hospital, Detroit, MI, 5University of Missouri, Columbia, MO, 6NYC Health and Hospital/Metropolitan Hospital, New York, NY, 7University of Kansas Medical Center, Kansas City, KS

    Background/Purpose: Vasculitides are characterized by inflammation of vessel walls with reactive damage to mural structures leading to compromise of the lumen. Vasculitides also accelerate atherosclerosis…
  • Abstract Number: 1560 • ACR Convergence 2022

    Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease

    Martina Bonacini1, Francesco Muratore1, Giovanna Restuccia2, Laura Albertazzi2, Piera Zaldini2, Luca Cimino3, Rossana Colla2, Alessandro Zerbini1, Carlo Salvarani4 and Stefania Croci1, 1Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 2Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy, 4Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Behçet disease (BD) is an inflammatory chronic disease characterized by alternation of active and inactive phases. Steroids, Colchine, Azathioprine (Aza) and interferon α are…
  • Abstract Number: 1617 • ACR Convergence 2022

    Direct Comparison of Ultrasound, [18F]Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging: Early Diagnostics in Patients Suspected of Giant Cell Arteritis

    Marieke van Nieuwland1, Marloes Vermeer1, Edgar Colin2, Nils Wagenaar1, Onno Vijlbrief1, Jordy van Zandwijk3, Riemer Slart4, Hendrik Koffijberg3, Erik Groot Jebbink3, Elisabeth Brouwer4, Dennis Boumans1 and Celina Alves1, 1Hospital Group Twente, Almelo, Netherlands, 2Hospital Group Twente, Deventer, Netherlands, 3University of Twente, Enschede, Netherlands, 4University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) requires rapid diagnostic work up and start of treatment to prevent severe complications. The temporal artery biopsy as a gold…
  • Abstract Number: 0438 • ACR Convergence 2022

    Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies

    Khai-Tuan Andrew Bui1, Rachel Richard2, Ariane Drouin3, Nader Toban1, Marianne Levesque4, Rosalie-Selene Meunier5, Carolyn Ross6 and Jean-Paul Makhzoum3, 1Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, 2Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Laval, QC, Canada, 3Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, 4Division of Respirology, Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, 5Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, 6University of Montreal, Montréal, QC, Canada

    Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in…
  • Abstract Number: 0470 • ACR Convergence 2022

    Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial

    Lisa Christ1, Luca Seitz2, Godehard Scholz1, Lukas Buetikofer3, Florian Kollert1, Stephan Reichenbach4 and Peter Villiger5, 1Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, 2Department of Rheumatology and Immunology, University of Bern, Inselspital, Switzerland, 3CTU Bern, University of Bern, Bern, Switzerland, 4University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, 5Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland

    Background/Purpose: Two randomised controlled trials (RCT) [1, 2] demonstrated a glucocorticoid (GC)-sparing effect of tocilizumab (TCZ) of at least 50% in the treatment of giant…
  • Abstract Number: 0526 • ACR Convergence 2022

    Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial

    Lynn Fussner1, Luis Felipe Flores-Suarez2, Rodrigo Cartin-Ceba3, Ulrich Specks3, P. Gerard Cox4, David Jayne5, Peter Merkel6 and Michael Walsh4, 1The Ohio State University, Columbus, OH, 2Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, 3Mayo Clinic, Rochester, MN, 4McMaster University, Hamilton, ON, Canada, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
  • Abstract Number: 1237 • ACR Convergence 2022

    Assessment of Common Femoral Vein Intima-Media Thickness by Ultrasound in Behçet’s Disease: Comparative Study of Patients with or Without Vascular Involvement in a National Referral Center

    Diana Prieto-Peña1, Alfonso del Peral-Fanjul2, Belén Atienza-Mateo1, Veronica Pulito-Cueto1, Miguel Ángel González-Gay3 and Ricardo Blanco4, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, Spain, 3Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Clinical vascular involvement is present in up to 40% of patients with Behçet’s disease (BD). Increased venous wall thickness assessed with ultrasound (US) has…
  • Abstract Number: 1561 • ACR Convergence 2022

    Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

    Didar Ucar1, Basak Ecem Bircan2, Nigar Rustamli3, Bilge Batu Oto1, Vedat Hamuryudan4, Sinem Nihal Esatoglu5 and gulen Hatemi5, 1Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Ophthalmology, Istanbul, Turkey, 2Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Istanbul, Turkey, 4Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells on slit lamp examination at the time of diagnosis. However, the prognostic…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology